New findings reported from K.M. Grimshaw and co-authors describe advances in xenografts

New research, 'AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth,' is the subject of a report. According to recent research from Cambridge, the United Kingdom, "The serine/threonine kinase AKT plays a pivotal role in signal transduction events involved in malignant transformation and chemoresistance and is an attractive target for the development of cancer therapeutics. Fragment-based lead discovery, combined with structure-based drug design, has recently identified AT7867 as a novel and potent inhibitor of both AKT and the downstream kinase p70 S6 kinase (p70S6K) and also of protein kinase...

Want to see the full article?

• Purchase this article for only $3.00